Aktuelle radiopharmazeutische Entwicklungen für die theranostische Anwendung

 

 Buy Article Permissions and Reprints

Abstract

Theranostics – a blend made up of the elements „therapy“ and „diagnostics“ – aims at the right therapy for the right patient at the right time. The article deals with the basics of the theranostic principle based on the characteristics of the radionuclides and their availability. Different types of theranostic radionuclide and radioligand pairs are described using medical and chemical examples from the most prominent areas of application in theranostics, which are prostate carcinoma, neuroendocrine tumours and fibroblast activation protein inhibitors. Furthermore, the article explains the regulatory framework conditions such as the availability and marketability of radionuclide precursors and radioactive pharmaceuticals as well as their in-house production.

Publication History

Article published online:
10 June 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

• Literatur

• 1 Fanti S, Bonfiglioli R, Decristoforo C. Highlights of the 30th annual congress of the EANM, Vienna 2017: „Yes we can – make nuclear medicine great again” . Eur J Nucl Med Mol Imaging 2018; 45: 1781-1794 DOI: 10.1007/s00259-018-4029-9.
  CrossrefPubMedGoogle Scholar
• 2 Schwarzenböck SM, Garibotto V. Highlights of the 32th annual congress of the EANM, Barcelona 2019: the nucleolympic games of nuclear medicine-a global competition for excellence. Eur J Nucl Med Mol Imaging 2020; 47: 1808-1819 DOI: 10.1007/s00259-020-04833-8.
  CrossrefPubMedGoogle Scholar
• 3 Hermann K, Schwaiger M, Lewis JS. et al. Radiotheranostics: a roadmap for future development. Lancet Oncol 2020; 21: e146-156 DOI: 10.1016/S1470-2045(19)30821-6.
  CrossrefPubMedGoogle Scholar
• 4 Carlucci G, Ippisch R, Slavik R. et al. 68Ga-PSMA-11 NDA Approval: a novel and successful academic partnership. J Nucl Med 2021; 62: 149-155 DOI: 10.2967/jnumed.120.260455.
  CrossrefPubMedGoogle Scholar
• 5 Sterzing F, Kratochwil C, Fiedler H. et al. (68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. Eur J Nucl Med Mol Imaging 2016; 43: 34-41 DOI: 10.1007/s00259-015-3188-1.
  CrossrefPubMedGoogle Scholar
• 6 Gasch C, Körber S, Kremer C. et al. Bedeutung und Nutzen von PSMA-Liganden beim Prostatakarzinom. Aktuelle Urol 2017; 48: 140-147 DOI: 10.1055/s-0043-100269.
  Article in Thieme ConnectPubMedGoogle Scholar
• 7 Hofman MS, Lawrentschuk N, Francis RJ. et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomized, multicentre study. The Lancet 2020; 395: 1208-1216 DOI: 10.1016/S0140-6736(20)30314-7.
  CrossrefPubMedGoogle Scholar
• 8 Ferraro D, Lehner F, Becker AS. et al. Improved oncological outcome after radical prostatectomy in patients staged with 68 Ga-PSMA-11 PET: a single-center retrospective cohort comparison. Eur J Nucl Med Mol Imaging 2021; 48: 1219-1228 DOI: 10.1007/s00259-020-05058-5.
  CrossrefPubMedGoogle Scholar
• 9 Hofman MS, Violet J, Hicks RJ. et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol 2018; 19: 825-833 DOI: 10.1016/S1470-2045(18)30198-0.
  CrossrefPubMedGoogle Scholar
• 10 Hofman MS, Emmett L, Sandhu S. et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomized, open-label, phase 2 trial. Lancet Oncol 2021; DOI: 10.1016/S0140–6736(21)00237–3.
  CrossrefPubMedGoogle Scholar
• 11 Rahbar K, Bodei L, Morris MJ. et al. Is the Vision of Radioligand Therapy for Prostate Cancer Becoming a Reality? An Overview of the Phase III VISION Trial and Its Importance for the Future of Theranostics. . J Nucl Med 2019; 60: 1504-1506 DOI: 10.2967/jnumed.119.234054.
  CrossrefPubMedGoogle Scholar
• 12 Zippel C, Giesel FL, Kratochwil C. et al. PSMA-Radioligandentherapie könnte Nuklearmedizin vor infrastrukturelle Herausforderungen stellen: Ergebnisse einer Basiskalkulation zur Kapazitätsplanung nuklearmedizinischer Betten im deutschen Krankenhaussektor. Nuklearmedizin 2021; DOI: 10.1055/a-1351–0030.
  Article in Thieme ConnectPubMedGoogle Scholar
• 13 Türler A. Matched pair theranostics. Chimia 2019; 73: 947-949 DOI: 10.2533/chimia.2019.947.
  CrossrefPubMedGoogle Scholar
• 14 Kesch C, Kratochwil C, Mier W. et al. 68Ga or 18F for prostate cancer imaging?. J Nucl Med 2017; 58: 687-688 DOI: 10.2967/jnumed.117.190157.
  CrossrefPubMedGoogle Scholar
• 15 Fersing C, Bouhlel A, Cantelli C. et al. A comprehensive review of non-covalent radiofluorination approaches using aluminum [18F]fluoride: Will [18F]AlF replace 68Ga for metal chelate labeling?. Molecules 2019; 24: 2866 DOI: 10.3390/molecules24162866.
  CrossrefPubMedGoogle Scholar
• 16 Pauwels E, Cleeren F, Tshibangu T. et al. [18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients. Eur J Nucl Med Mol Imaging 2020; 47: 3033-3046 DOI: 10.1007/s00259-020-04918-4.
  CrossrefPubMedGoogle Scholar
• 17 Giesel FL, Cardinale J, Schäfer M. et al. 18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617. Eur J Nucl Med Mol Imaging 2016; 43: 1929-1930 DOI: 10.1007/s00259-016-3447-9.
  CrossrefPubMedGoogle Scholar
• 18 Rodnick M, Sollert C, Stark D. et al. Cyclotron-based production of 68Ga, [68Ga]GaCl3, and [68Ga]Ga-PSMA-11 from a liquid target. EJNMMI Radiopharm Chem 2020; 5: 25 DOI: 10.1186/s41181–020–00106–9.
  CrossrefPubMedGoogle Scholar
• 19 Thisgaard H, Kumlin J, Langkjær N. et al. Multi-curie production of gallium-68 on a biomedical cyclotron and automated radiolabelling of PSMA-11 and DOTATATE. EJNMMI Radiopharm Chem 2021; 6: 1 DOI: 10.1186/s41181–020–00114–9.
  CrossrefPubMedGoogle Scholar
• 20 Notni J, Wester HJ. Re‐thinking the role of radiometal isotopes: Towards a future concept for theranostic radiopharmaceuticals. J Labelled Comp Radiopharm 2018; 61: 143-156 DOI: 10.1002/jlcr.3582.
  CrossrefPubMedGoogle Scholar
• 21 Quaim SM, Scholten B, Neumaier B. New developments in the production of theranostic pairs of radionuclides. J Radioanal Nucl Chem 2018; 318: 1493-1509 DOI: 10.1007/s10967-018-6238-x.
  CrossrefPubMedGoogle Scholar
• 22 Müller C, Zhernosekov K, Köster U. et al. A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α- and β−-radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative. J Nucl Med 2012; 53: 1951-1959 DOI: 10.2967/jnumed.112.107540.
  CrossrefPubMedGoogle Scholar
• 23 Mikolajczak R, van der Meulen NP, Lapi SE. Radiometals for imaging and theranostics, current production, and future perspectives. J Labelled Comp Radiopharm 2019; 62: 615-634 DOI: 10.1002/jlcr.3770.
  CrossrefPubMedGoogle Scholar
• 24 Uccelli L, Martini P, Cittanti C. et al. Therapeutic radiometals: worldwide scientific literature trend analysis (2008–2018). Molecules 2019; 24: 640 DOI: 10.3390/molecules24030640.
  CrossrefPubMedGoogle Scholar
• 25 Singh A, van der Meulen NP, Müller C. et al. First-in-human PET/CT imaging of metastatic neuroendocrine neoplasms with cyclotron-produced 44Sc-DOTATOC: a proof-of-concept study. Cancer Biother Radiopharm 2017; 32: 124-32 DOI: 10.1089/cbr.2016.2173.
  CrossrefPubMedGoogle Scholar
• 26 Baum RP, Singh A, Benešová M. et al. Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with 152Tb-DOTATOC. Dalton Trans 2017; 46: 14638-14646 DOI: 10.1039/c7dt01936j.
  CrossrefPubMedGoogle Scholar
• 27 Baum RP, Singh A, Kulkarni HR. et al. First-in-human application of Terbium-161: A feasibility study using 161Tb-DOTATOC. J Nucl Med 2021; DOI: 10.2967/jnumed.120.258376.
  CrossrefPubMedGoogle Scholar
• 28 Müller C, Domnanich KA, Umbricht CA. et al. Scandium and Terbium radionuclides for radiotheranostics: current state of development towards clinical application. Br J Radiol 2018; 91 DOI: 10.1259/bjr.20180074.
  CrossrefPubMedGoogle Scholar
• 29 Van der Meulen NP, Hasler R, Talip Z. et al. Developments toward the implementation of 44Sc production at a medical cyclotron. Molecules 2020; 25: 4706 DOI: 10.3390/molecules25204706.
  CrossrefPubMedGoogle Scholar
• 30 NucAdvisor, Technopolis Group. European study on medical, industrial and research applications of nuclear and radiation technology final report: contract ENER/17/NUCL/SI2.755660. 2019 Verfügbar unter (Stand 30.04.2021): DOI: 10.2833/511137 https://op.europa.eu/en/publication-detail/-/publication/6ae3e9cd-2e7a-11e9–8d04–01aa75ed71a1/language-en
  CrossrefPubMedGoogle Scholar
• 31 Duchemin C, Ramos JP, Stora T. et al. CERN-MEDICIS: A unique facility for the production of nonconventional radionuclides for the medical research. 11th Int Particle Acc Conf 2020; DOI: 10.18429/JACoW-IPAC2020-THVIR13.
  CrossrefPubMedGoogle Scholar
• 32 Europäische Kommission. SAMIRA: Strategic agenda for medical ionising radiation applications. 2021 Verfügbar unter (Stand 30.04.2021): https://ec.europa.eu/energy/sites/default/files/swd_strategic_agenda_for_medical_ionising_radiation_applications_samira.pdf
  PubMedGoogle Scholar
• 33 Morgenstern A, Apostolidis C, Bruchertseifer F. Supply and clinical application of actinium-225 and bismuth-213. Sem Nucl Med 2020; 50: 119-123 DOI: 10.1053/j.semnuclmed.2020.02.003.
  CrossrefPubMedGoogle Scholar
• 34 IAEA und Europäische Kommision. Report on Joint Iaea-Jrc Workshop „Supply of Actinium-225”. 2018 Verfügbar unter (Stand 30.04.2021): http://www-naweb.iaea.org/napc/iachem/working_materials/Report_Workshop%20on%20Supply%20of%20Ac-225_IAEA_JRC_October2018.pd
  PubMedGoogle Scholar
• 35 Roscher M, Bakos G, Benešová M. Atomic nanogenerators in targeted alpha therapies: Curie’s legacy in modern cancer management. Pharmaceuticals 2020; 13: 76 DOI: 10.3390/ph13040076.
  CrossrefPubMedGoogle Scholar
• 36 Kelly J, Amor-Coarasa A, Sweeney E. et al. A Consensus Time for Performing Quality control of 225Ac-labeled radiopharmaceuticals. EJNMMI Radiopharm Chem Vorabveröffentlichung 2020; DOI: 10.21203/rs.3.rs-39342/v1.
  CrossrefPubMedGoogle Scholar
• 37 Koustoulidou S, Hoorens MWH, Dalm SU. et al. Cancer-associated fibroblasts as players in cancer development and progression and their role in targeted radionuclide imaging and therapy. Cancers 2021; 13: 1100 DOI: 10.3390/cancers13051100.
  CrossrefPubMedGoogle Scholar
• 38 Giesel FL, Kratochwil C, Lindner T. et al. 68Ga-FAPI PET/CT: Biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med 2019; 60: 386-392 DOI: 10.2967/jnumed.118.215913.
  CrossrefPubMedGoogle Scholar
• 39 Land Rheinland-Pfalz, Landesamt für Jugend, Soziales und Versorgung. Anzeige nach § 67 Abs. 2 Arzneimittelgesetz (AMG) für die erlaubnisfreie Herstellung von Arzneimitteln durch Ärzte und zur Ausübung der Heilkunde bei Menschen befugten Personen nach § 13 Abs. 2b AMG. Verfügbar unter (Stand 30.04.2021): https://lsjv.rlp.de/fileadmin/lsjv/Dateien/Aufgaben/Gesundheit/Arzneimittelueberwachung/AMG_Formblatt_67_2.pdf
  PubMedGoogle Scholar
• 40 Land Hessen, Regierungspräsidium Darmstadt. Anzeige nach § 67 Abs. 1 und 2 Arzneimittelgesetz (AMG) für die erlaubnisfreie Herstellung von Arzneimitteln durch ärztliche, zahnärztliche oder andere zur Ausübung der Heilkunde bei Menschen befugte Personen (Formular für ärztliche, zahnärztliche sowie sonst zur Ausübung der Heilkunde beim Menschen befugte Personen). Verfügbar unter (Stand 30.04.2021): https://rp-darmstadt.hessen.de/sites/rp-darmstadt.hessen.de/files/20191010_%C2%A767AMG_Anzeige_Arzt_Zahnarzt_HP.pdf
  PubMedGoogle Scholar
• 41 Land Baden-Württemberg. Anzeige nach § 67 Arzneimittelgesetz (AMG) zur erlaubnisfreien Herstellung von Arzneimitteln durch Ärzte, Zahnärzte oder sonst zur Ausübung der Heilkunde bei Menschen befugte Personen (Heilpraktiker) gemäß § 13 Absatz 2b AMG oder § 20d AMG. Verfügbar unter (Stand 30.04.2021): https://rp.baden-wuerttemberg.de/fileadmin/RP-Internet/Themenportal/Gesundheit/_DocumentLibraries/Gesundheits-Dokumente/Arzneimittelherstellung/Anzeige_Arzt_Heilpraktiker___67_AMG.pdf
  PubMedGoogle Scholar
• 42 Zentralstelle der Länder für Gesundheitsschutz bei Arzneimitteln und Medizinprodukten. Auslegungshilfe für die Überwachung der erlaubnisfreien Herstellung von sterilen Arzneimitteln, insbesondere Parenteralia, durch Ärzte oder sonst zur Heilkunde befugte Personen gemäß § 13 Abs. 2b Arzneimittelgesetz (AMG). 2018 Verfügbar unter (Stand 30.04.2021): https://www.zlg.de/index.php?eID=dumpFile&t=f&f=649&token=da199309acfdbfabc73ad406c45c27971fb17cfc
  PubMedGoogle Scholar
• 43 Zentralstelle der Länder für Gesundheitsschutz bei Arzneimitteln und Medizinprodukten. Aide-Mémoire 07120804: Überwachung der Herstellung von Radiopharmaka 2018. Verfügbar unter (Stand 30.04.2021): https://www.zlg.de/index.php?eID=dumpFile&t=f&f=5336&token=b5912c88a8904cf790213827e058be11fb29135f
  PubMedGoogle Scholar
• 44 Hoppe U, Machulla HJ, Neumaier B. Zur Situation der erlaubnisfreien Selbstherstellung von Radiopharmaka in der Nuklearmedizin. Nuklearmedizin 2013; 52 (Suppl. 05) N53 DOI: 10.1055/s-0038–1625757.
  Article in Thieme ConnectPubMedGoogle Scholar
• 45 Hofmann M, Maecke H, Börner R. et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001; 28: 1757-1757 DOI: 10.1007/s002590100639.
  CrossrefPubMedGoogle Scholar
• 46 Forrer F, Uusijärvi H, Storch D. et al. Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC. J Nucl Med 2005; 46: 1310-1316
  PubMedGoogle Scholar
• 47 Weineisen M, Schottelius M, Simecek J. et al. 68Ga- and 177Lu-labeled PSMA I&T: Optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med 2015; 56: 1159-1165 DOI: 10.2967/jnumed.115.158550.
  CrossrefPubMedGoogle Scholar
• 48 Paterson B, Roselt P, Denoyer D. et al. PET imaging of tumours with a 64Cu labeled macrobicyclic cage amine ligand tethered to Tyr3-octreotate. Dalton Trans 2014; 43: 1386-1396 DOI: 10.1039/c3dt52647j.
  CrossrefPubMedGoogle Scholar
• 49 Hicks R, Jackson P, Kong G. et al. 64Cu-SARTATE PET Imaging of patients with neuroendocrine tumors demonstrates high tumor uptake and retention, potentially allowing prospective dosimetry for peptide receptor radionuclide therapy. J Nucl Med 2019; 60: 777-785 DOI: 10.2967/jnumed.118.217745.
  CrossrefPubMedGoogle Scholar
• 50 Cullinane C, Jeffery CM, Roselt PD. et al. Peptide receptor radionuclide therapy with 67cu-cusartate is highly efficacious against a somatostatin-positive neuroendocrine tumor model. J Nucl Med 2020; 61: 1800-1805 DOI: 10.2967/jnumed.120.243543.
  CrossrefPubMedGoogle Scholar
• 51 Europäische Arzneimittelbehörde (EMA). European public assessment report (EPAR) for SomaKit TOC. 2020 Verfügbar unter (Stand 30.04.2021): https://www.ema.europa.eu/en/medicines/human/EPAR/somakit-toc
  PubMedGoogle Scholar
• 52 Europäische Arzneimittelbehörde (EMA). European public assessment report (EPAR) for Lutathera. 2021 Verfügbar unter (Stand 30.04.2021): https://www.ema.europa.eu/en/medicines/human/EPAR/lutathera
  PubMedGoogle Scholar
• 53 Eder M, Schäfer M, Bauder-Wüst U. et al. 68Ga-complex lipophilicity and the targeting property of a urea-based psma inhibitor for PET imaging. Bioconjugate Chem 2012; 23: 688-697 DOI: 10.1021/bc200279b.
  CrossrefPubMedGoogle Scholar
• 54 Afshar-Oromieh A, Haberkorn U, Eder M. et al. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: Comparison with 18F-FECh. Eur J Nucl Med Mol Imaging 2012; 39: 1085-1086 DOI: 10.1007/s00259-012-2298-2.
  CrossrefPubMedGoogle Scholar
• 55 Benešová M, Schäfer M, Bauder-Wüst U. et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med 2015; 56: 914-920 DOI: 10.2967/jnumed.114.147413.
  CrossrefPubMedGoogle Scholar
• 56 Kratochwil C, Giesel FL, Eder M. et al. [177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imag 2015; 42: 987-988 DOI: 10.1007/s00259-014-2978-1.
  CrossrefPubMedGoogle Scholar